Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NA-17.A2
- Development stage
- Phase 3
- Lead developer
- Ludwig Cancer Research
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intradermal
01
Overview
NA-17.A2 (also known as NA17.A2) is a synthetic peptide-based cancer vaccine developed by the Ludwig Institute for Cancer Research (LICR) for the treatment of melanoma. The vaccine consists of a peptide sequence derived from the NA17 antigen, which is a product of the N-acetylglucosaminyltransferase V (GnT-V) gene. This antigen is specifically presented on the surface of tumor cells by HLA-A2 molecules. NA-17.A2 is designed to stimulate the immune system, particularly cytotoxic T lymphocytes (CTLs), to recognize and destroy melanoma cells expressing the NA17 antigen. It has been investigated in Phase I/II clinical trials, often in combination with adjuvants such as CpG 7909 to enhance the magnitude and duration of the anti-tumor immune response.
- Other names
- NA17 peptideNA-17 peptideNA 17 peptideNA17.A2 peptideNA-17.A2 peptideNA 17.A2 peptide
02
Targets
MGAT5 (N-acetylglucosaminyltransferase V)HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)T cell receptor specific for NA17-A peptide presented by HLA-A*02:01
Beyond the preview
Go deeper on NA-17.A2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NA-17.A2.